0001209191-19-008750.txt : 20190208 0001209191-19-008750.hdr.sgml : 20190208 20190208190949 ACCESSION NUMBER: 0001209191-19-008750 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190206 FILED AS OF DATE: 20190208 DATE AS OF CHANGE: 20190208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shukla Sanjay CENTRAL INDEX KEY: 0001671026 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 19581463 MAIL ADDRESS: STREET 1: C/O ATYR PHARMA, INC. STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-06 0 0001339970 aTYR PHARMA INC LIFE 0001671026 Shukla Sanjay 3545 JOHN HOPKINS COURT, SUITE #250 SAN DIEGO CA 92121 0 1 0 0 President and CEO Employee Stock Option (right to buy) 0.5172 2019-02-06 4 A 0 200000 0.00 A 2029-02-06 Common Stock 200000 200000 D Restricted Stock Unit 2019-02-06 4 A 0 50000 0.00 A Common Stock 50000 50000 D The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2019, such that this option will be fully exercisable on February 6, 2023. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Nancy D. Krueger, attorney-in-fact 2019-02-08